An evaluation of the mode of action framework for mutagenic carcinogens case study II: Chromium (VI)

Environmental and Molecular Mutagenesis

Volumn 51, Issue 2, 2010, Pages 89-111

  McCarroll, Nancy ^a   Keshava, Nagalakshmi ^a   Chen, Jonathan ^a   Akerman, Gregory ^a   Kligerman, Andrew ^b   Rinde, Esther ^a  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^b U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

Cr (VI); Hexavalent chromium; Mode of action; Mutagenicity

Indexed keywords

ANION CHANNEL; CARCINOGEN; CHROMIUM; DICHROMATE SODIUM; DNA; DRINKING WATER; FREE RADICAL; POTASSIUM CHROMATE; PROTEIN P53;

ADENOMA; APOPTOSIS; BASAL CELL CARCINOMA; BASE PAIRING; BURKITT LYMPHOMA; CARCINOGENESIS; CARCINOGENICITY; CASE STUDY; CELL HYPERPLASIA; CELL INTERACTION; CELL PROLIFERATION; CHROMOSOME ABERRATION; CYSTIC LYMPHANGIOMA; CYTOTOXICITY; DATA BASE; DNA ADDUCT; DNA CROSS LINKING; DNA DAMAGE; DNA FRAGMENTATION; DNA METABOLISM; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DUODENUM CANCER; EMBRYO DEVELOPMENT; EPSTEIN BARR VIRUS; ESCHERICHIA COLI; GASTROINTESTINAL TUMOR; GENE DELETION; GENE INACTIVATION; GENE MUTATION; GENE SEQUENCE; GENETIC DAMAGE; GENETIC TOXICOLOGY; GENOTOXICITY; GERM CELL; HISTIOCYTE; HUMAN; IN VITRO STUDY; INHALATION; JEJUNUM TUMOR; LIPID PEROXIDATION; METABOLIC DISORDER; MICRONUCLEUS; MOUTH CANCER; MUTAGENESIS; MUTAGENICITY; NONHUMAN; NOSE TUMOR; OCCUPATIONAL EXPOSURE; OXIDATIVE STRESS; POINT MUTATION; PRACTICE GUIDELINE; PROTEIN DNA INTERACTION; REVIEW; RISK ASSESSMENT; SALMONELLA TYPHIMURIUM; SARCOMA; SINGLE STRANDED DNA BREAK; SQUAMOUS CELL CARCINOMA; TOXICOKINETICS; TUMOR SUPPRESSOR GENE; WATER ANALYSIS;

ANIMALS; CARCINOGENS, ENVIRONMENTAL; CHROMIUM; DNA DAMAGE; GUIDELINES AS TOPIC; HUMANS; MUTAGENICITY TESTS; MUTAGENS; NEOPLASMS; RISK ASSESSMENT;

ANIMALIA; MUS; RATTUS; RODENTIA;

EID: 77249118332     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.20525     Document Type: Review

References (98)

1. Agency for Toxic Substances and Disease Registry (ATSDR). 2000. Toxicological Profile for Chromium, prepared by Syracuse Research Corporation Under Contract No. 205-199-00024 for U.S. Department of Health and Human Services, Public Health Service, Atlanta, Georgia. pp 1-149.
2. Agency for Toxic Substances and Disease Registry (ATSDR). 2008. Toxicological profile for Chromium (Draft for Public Comment). Atlanta, GA: U.S. Department of Health and Human Services, Public Health Service.
3. Baetjer AM, Damron C, Sudacz V. 1959. The distribution and retention of chromium in men and animals. AMA Arch Ind Health 20:136-150.
4. Bagchi D, Hassoun EA, Bagchi M, Muldoon DF, Stohs SJ. 1995a. Oxidative stress induced by chronic administration of sodium dichromate. Comp Biochem Physiol C 110:281-287.
5. Bagchi D, Hassoun EA, Bagchi M, Stohs SJ. 1995b. Chromium-induced excretion of urinary lipid metabolites, DNA damage, nitric oxide production, and generation of reactive oxygen species in Sprague-Dawley rats. Comp Biochem Physiol C 110:177-187.
6. Bagchi D, Vuchetich PJ, Bagchi M, Hassoun EA, Tran L, Stohs SJ. 1997. Induction of oxidative stress by chronic administration of sodium dichromate [Chromium VI] and cadmium chloride [Cadmium II] to rats. Free Radical Biol Med 22:471-478.
7. Bagchi D, Bagchi M, Stohs SJ. 2001. Chromium (VI)-induced oxidative stress, apoptotic cell death and modulation of p53 tumor suppressor gene. Mol Cell Biochem 222:149-158.
8. Bagchi D, Balmoori J, Bagchi M, Ye X, Williams CB, Stohs SJ. 2002. Comparative effects of TCCD, endrin, naphthalene and chromium (VI) on oxidative stress and tissue damage in the liver and brain tissues of mice. Toxicology 175:73-82.
9. Beaumont J, Sedman RM, Stephen D, Reynolds SD, Sherman CD, Li L, Howd RA, Sandt MS, Zeise L, Alexeeff GV. 2008. Cancer mortality in a Chinese population exposed to hexavalent chromium in drinking water. Epidemiology 19:12-23.
10. Benova D, Hadjidekova V, Hristova R, Nikolova T, Boulanova M, Gerogieva I, Grigorova M, Popov T, Paney T, Gerogieva R, Natarajan AT, Darroudi F, Nilsson R. 2003. Cytogenetic effects of hexavalent chromium in Bulgarian chromium workers. Mutat Res 538:181-182.
11. Bigaliev A, Turebaev M, Elemesova M. 1977. Cytogenetic study of the in vivo mutagenic properties of chromium compounds. In: Dubinin NP, editor. Genet Posledstviya Zagryanenia Okruzhayushehei Sredy (Proceedings of the Symposium). Moscow: Nauka. pp.173-176.
12. Bridgewater LC, Manning FC, Patierno SR. 1994. Base-specific arrest of in vitro DNA replication by carcinogenic chromium: Relationship to DNA interstrand crosslinking. Carcinogenesis 15:2421-2427.
13. Bridgewater LC, Manning FC, Patierno SR. 1998. Arrest of replication by mammalian DNA polymerases a and b caused by chromium-DNA lesions. Mol Carcinogen 23:201-206.
14. Briggs JA, Briggs RC. 1988. Characterization of chromium effects on a rat liver epithelial cell line and their relevance to in vitro transformation. Cancer Res 48:6484-6490.
15. Chen F, Ye J, Zhang X, Rojanasakul Y, Shi X. 1997. One-electron reduction of chromium (VI) by a-lipoic acid and related hydroxyl radical generation, dG hydroxylation and nuclear transcription factor-κB activation. Arch Biochem Biophys 338:165-172.
16. Chorvatovičová D, Ginter E. 1989. Effects of Cr VI, vitamin C in transplacental micronucleus test in mice. Biologia 44:1033-1038.
17. Coogan TP, Motz J, Snyder CA, Squibb KS, Costa M. 1991. Differential DNA-protein crosslinking in lymphocytes and liver following chronic drinking water exposure of rats to potassium chromate. Toxicol Appl Pharmacol 109:60-72.
18. Costa M, Klein CB. 2006. Toxicity and carcinogenicity of chromium compounds in humans. Crit Rev Toxicol 36:115-163.
19. Danadevi K, Rozati R, Saleha Banu B, Jamil K, Grover P. 2001. In vivo genotoxic effects of potassium dichromate in mice leukocytes using comet assay. Food Chem Toxicol 39:859-865.
20. Danadevi K, Rozati R, Saleha Banu B, Grover P. 2004. Genotoxic evaluation of welders occupationally exposed to chromium and nickel using the Comet assay and micronucleus assays. Mutagen 19:35-41.
21. Davidson T, Kluz T, Burns F, Rossman T, Zhang Q, Uddin A, Nadas A, Costa M. 2004. Exposure to chromium (VI) in drinking water increases susceptibility to UV-induced skin tumors in hairless mice. Toxicol Appl Pharmacol 196:431-437.
22. Dearfield KL, Moore MM. 2005. Use of genetic toxicology information for risk assessment. Environ Mol Mutagen 46:236-245.
23. De Flora S, Camoirano A, Bagnasco M, Bennicelli C, Corbett GE, Kerger BD. 1997. Estimates of the chromium (VI) reducing capacity in human body compartments as a mechanism for attenuating its potential toxicity and carcinogenicity. Carcinogenesis 18:531-537.
24. De Flora S, Ilcheva M, Balansky RM. 2006. Oral chromium (VI) does not affect the frequency of micronuclei in hematopoietic cells of adult mice and of transplacentally exposed fetuses. Mutat Res 610:38-47.
25. De Flora S, D'Agostini FD, Balansky R, Micale R, Baluce B, Izzotti A. 2008. Lack of genotoxic effects in hematopoietic and gastrointestinal cells of mice receiving chromium (VI) with drinking water. Mutat Res 659:60-67.
26. Dunkel VC, Pienta RJ, Sivak A, Traul KA. 1981. Comparative neoplastic transformation responses of Balb/3T3 cells, Syrian hamster embryo cells, and Rauscher murine leukemia virus-infected Fischer 344 rat embryo cells to chemical carcinogens. J Natl Cancer Inst 67:1303-1315.
27. Edel J, Sabbioni E. 1985. Pathways of Cr (III) and Cr (VI) in the rat after intratracheal administration. Hum Toxicol 4:409-416.
28. European Commission DG ENV. E3. 2002. Heavy metals in waste. Final Report, Project ENV.E. 3/ETU/2000/0058.
29. Febel H, Szegedi B, Huszar S. 2001. Absorption of inorganic, trivalent and hexavalent chromium following oral and intrajejunal doses in rats. Acta Vet Hung 49:203-209.
30. Flores A, Perez JM. 1999. Cytotoxicity, apoptosis, and in vitro DNA damage induced by potassium chromate. Toxicol Appl Pharmacol 161:75-81.
31. Fornace AY, Seres DS, Lanchner SF, Harrie CC. 1981. DNA-protein cross-linking by chromium salts. Chem Biol Interact 36:345-354.
32. Gambelunghe A, Piccinini R, Ambrogi M, Villarini M, Moretti M, Marchetti C, Abbritti G, Muzi G. 2003. Primary DNA damage in chrome-plating workers. Toxicology 188:187-195.
33. Gibb HJ, Lees PSJ, Pinsky PF, Rooney B. 2000. Lung cancer among workers in chromium chemical production. Am J Ind Med 38:115-126.
34. Gruber JE, Jennette KW. 1978. Metabolism of the carcinogen chromate by rat liver microsomes. Biochem Biophys Res Commun 82:700-706.
35. Haworth S, Lawlor T, Mortelmans K, Speck W. 1983. Salmonella mutagenicity test results for 250 chemicals. Environ Mutag Suppl l 1:3-142.
36. Hill R, Leidal AM, Madureira PA, Gillis LD, Cochrane HK, Waisman DM, Chiu A, Lee PW. 2008. Hypersensitivity to chromium-induced DNA damage correlates with constitutive deregulation of upstream p53 kinases in p21-/- HCT116 colon cancer cells. DNA Repair (Amst) 7:239-52.
37. IARC. 1990. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans: Chromium and chromium compounds, Vol. 49. Lyon: International Agency for Research on Cancer, Lyon. pp. 49-214.
38. IARC. 1997. Monographs on Chromium, Nickel, and Welding. Lyon: International Agency for Research on Cancer, pp. 17-34 (Updated November 5, 1997).
39. Itoh S, Shimada H. 1996. Micronucleus induction by chromium and selenium, and suppression of metallothionein inducer. Mutat Res 367:233-236.
40. Itoh S, Shimada H. 1998. Bone marrow and liver mutagenesis in lacZ transgenic mice treated with hexavalent chromium. Mutat Res 412:63-67.
41. Jennette KW. 1979. Chromate metabolism in liver microsomes. Biol Trace Elem Res 1:55-62.
42. Kanojia RK, Junaid M, Murthy RC. 1996. Chromium induced teratogenicity in female rats. Toxicol Lett 89:207-213.
43. Kidwell J. 2008. Inorganic hexavalent chromium (Cr(VI)): Report of the Cancer Assessment Review Committee. TXR 0054811 (dated March 12, 2008).
44. Kidwell J. 2009. Inorganic hexavalent chromium (Cr(VI)): Revised report of the Cancer Assessment Review Committee. TXR 0055224 (dated July 1, 2009).
45. Kirkland D, Aardema M, Muller l, Hayashi M. 2006. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens II. Further analysis of mammalian cell results, relative predictivity and tumor profiles. Mutat Res/Gen Toxicol Environ Mutat 608:29-42.
46. Kirpnick-Sobol Z, Reliene R, Schiest RH. 2006. Carcinogenic Cr(VI) and the nutritional supplement Cr(III) induce DNA deletions in yeast and mice. Cancer Res 66:3480-3484.
47. Knudsen I. 1980. The mammalian spot test and its use for the testing of potential carcinogenicity of welding fume particles and hexavalent chromium. Acta Pharm Toxicol 47:66-70.
48. Langård S. 1990. One hundred years of chromium and cancer: A review of epidemiological evidence and selected case reports. Am J Ind Med 17:189-215.
49. Lohman PHM, Lohman WJA 2000. Genetic activity profiles of short-term testing data from the US EPA and from IARC monographs. GAP2000 version 1.3 for Windows, 2000.
50. 2 Fenton-like reaction causes DNA damage: Implications to chromate's genotoxicity. Ann Clin Lab Sci 26:185-191.
51. Manning FCR, Blankenship LJ, Wise JP, Xu J, Bridgewater LC, Patierno SR (1994). Induction of internucleosomal DNA fragmentation by carcinogenic chromate: Relationship to DNA damage, genotoxicity, and inhibition of macromolecular synthesis. Environ Health Perspect 102 (Suppl. 3):159-167.
52. Meek ME (Bette), Bucher JR, Cohen SM, Dellarco V, Hill RN, Lehman-McKeeman LD, Longfellow DG, Pastoor T, Seed J, Patton DE. 2003. A framework for human relevance analysis of information on carcinogenic modes of action. Crit Rev Toxicol 33:591-654.
53. McCarroll NE, Protzel A, Ioannou Y, Stack HF, Jackson MA, Waters MD, Dearfield KL. 2002. A survey of EPA/OPP and open literature on selected pesticide chemicals III. Mutagenicity and carcinogenicity of benomyl and carbendazim. Mutat Res 512:1-35.
54. McCarroll N, Keshava N, Cimino M, Chu M, Dearfield K, Keshava C, Kligerman A, Owen R, Protzel A, Putzrath R, Schoney R. 2008. An evaluation of the mode of action framework for mutagenic carcinogens case study: Cyclophosphamide. Environ Mol Mutag 49:117-131.
55. McGregor DB, Martin R, Cattanach P, Edwards I, McBride D, Caspary WJ. 1987. Responses of the L5178Y tk+/tk- mouse lymphoma cell forward mutation assay to coded chemicals. I. Results for nine compounds. Environ Mutag 9:143-160.
56. Mirsalis JC, Hamilton CM, O'Loughlin KG, Paustenbach DJ, Kerger BD, Patierno S. 1996. Chromium (VI) at plausible drinking water concentrations is not genotoxic in the in vivo bone marrow micronucleus or liver unscheduled DNA synthesis assays. Environ Mol Mutag 28:60-63.
57. National Toxicology Program (NTP). 2007. NTP technical report on the toxicity studies of sodium dichromate dihydrate (CAS No. 7789-12-0) administered in drinking water to male and female F344/N rats and B6C3F1 mice and male BALB/c and am3-C57BL/6 mice. Southern Research Institute, Birmingham, AL. NTP TR 72 (NIH Publication No. 07-5964), January 2007. Published by the National Institutes of Health, U.S. Department of Health and Human Services. MRID 47325704.
58. National Toxicology Program (NTP). 2008. NTP toxicology and carcinogenesis studies of sodium dichromate dihydrate (CAS No. 7789-12-0) in F344/N rats and B6C3F1 mice (drinking water studies). Natl Toxicol Prog Tech Rep Ser 546:1-192. MRID No. 47325703.
59. Paschin YV, Zacepilova TA, Kozachenko VI. 1982. Induction of dominant lethal mutations in male mice by potassium dichromate. Mutat Res 103:345-347.
60. Paschin YV, Kozachenko VI, Sal'nikova LE. 1983. Differential mutagenic response at the HGPRT locus in V79 and CHO Chinese hamster cells after treatment with chromate. Mutat Res 122:361-365.
61. Pitot HC III, Dragan YP. 2001. Chemical carcinogenesis. In: Klaassen CD, editor. Cassarett and Doull's Toxicology: The Basic Science of Poisons, 5th ed. New York: McGraw-Hill. pp. 201-267.
62. Preston RJ, Williams GM. 2005. DNA-reactive carcinogens: Mode of action and human cancer hazard. Crit Rev Toxicol 35:673-683.
63. Procter DM, Otani JM, Finley BL, Paustenbach DJ, Bland JA, Speizer N, Sargent EV. 2002. Is hexavalent chromium carcinogenic via ingestion? A weight of the evidence review. J Toxicol Environ Health A 65:701-746.
64. Quievryn G, Messer J, Zhitkovich A. 2002. Carcinogenic chromium (VI) induces cross-linking of vitamin C to DNA in vitro and in human lung A549 cells. Biochemistry 41:3156-3167.
65. Salnikow K, Zhitkovich A. 2008. Genetic and epigenetic mechanisms in metal carcinogenesis and cocarcinogenesis: Nickel, arsenic and chromium. Chem Res Toxicol 21:28-44.
66. Sander M, Cadet J, Casciano DA, Galloway SM, Marnett LJ, Novak RF, Pettit SD, Preston RJ, Skare JA, Williams GM, Van Houten B, Gollapudi BB. 2005. Proceedings of a workshop on DNA adducts: Biological significance and applications to risk assessment Washington DC, April 13-14, 2004. Toxicol Appl Pharmacol 208:1-20.
67. Sarkar D, Sharma A, Talukder G. 1993. Differential protection of chlorophyllin against chromium and chlordane in mouse bone marrow in vivo. Mutat Res Lett 301:33-38.
68. Sarto F, Levis AG, Paulon C. 1980. Clastogenic activity of hexavalent and trivalent chromium in cultured human lymphocytes. Caryologia 33:239-250.
69. Sedman RM, Beaumont J, McDonald TA, Reynolds S, Keowech G, Howd R. 2006. Review of the evidence regarding the carcinogenicity of hexavalent chromium in drinking water. J Environ Sci Health Part C 24:155-182.
70. Seoane AI, Dulout FN. 1999. Contribution of the validation of the anaphase-test: Aneugenic and clastogenic effects of cadmium sulfate, potassium dichromate and nickel chloride in Chinese hamster ovary cells. Genet Mol Biol 22:551-555.
71. Shi X, Dalal NS. 1992. The role of superoxide radical in chromium (VI) generated hydroxyl radical: The Cr(VI) Haber-Weiss cycle. Arch Biochem Biophys 292:323-327.
72. Shi X, Dalal NS. 1994. On the mechanism of generation of hydroxyl radical by chromate in biologically relevant systems: Role of Cr(VI) complexes versus tetraperoxochromate (V). Environ Health Perspect 102:231-236.
73. Shi X, Chiu A, Chen CT, Halliwell B, Castranova V, Vallyathan V. 1999. Reduction of chromium (VI) and its relationship to carcinogenesis. J Toxicol Environ Health B 2:87-104.
74. Shindo Y, Toyoda Y, Kawamura K, Kurebe M, Shimada H, Chidharu H, Satake S. 1989. Micronucleus test with potassium chromate (VI) administered intraperitoneally and orally to mice. Mutat Res 223:403-406.
75. Shrivastava HY, Ravikumar T, Shanmugasundaram M, Babu M, Nair BU. 2005. Cytotoxicity studies of chromium (III) complexes on human dermal fibroblasts. Free Radical Biol Med 38:58-69.
76. Singh I. 1983. Induction of reverse mutations and mitotic gene conversion by some metal compounds in Saccharomyces cerevisae. Mutat Res 117:149-152.
77. Snow ET, Xu L-S. 1991. Chromium (III) bound to DNA templates promotes increased polymerase processivity and decreased fidelity during replication in vitro. Biochemistry 30:11238-11245.
78. Stella M, Montaldi A, Rossi R, Rossi G, Levis AG. 1982. Clastogenic effects of chromium on human lymphocytes in vitro and in vivo. Mutat Res 101:151-164.
79. Sugiyama M. 1992. Role of physiological antioxidants in chromium VI-induced cellular injury. Free Biol Med 12:397-407.
80. Sugden KD, Stearns DM. 2000. The role of chromium (V) in the mechanism of chromate-induced oxidative DNA damage and cancer. J Environ Path Toxicol Onco 19:215-230.
81. Swenberg JA, Fryar-Tita E, Jeong Y-C, Boysen G, Starr T, Walker VE, Albertini RJ. 2008. Biomarkers in toxicology and risk assessment: Informing critical dose-response relationships. Chem Res Toxicol 21:253-265.
82. Umeda M, Nishimura M. 1979. Inducibility of chromosomal aberrations by metal compounds in cultured mammalian cells. Mutat Res 67:221-229.
83. USEPA. 2005a. Guidelines for carcinogenic risk assessments, EPA/630/ P-03/001F, March 2005 (http://www.epa.gov/cancer guidelines).
84. USEPA. 2005b. Supplemental guidance for assessing cancer susceptibility from early-life exposure to carcinogens, EPA/630/R-03/003F, March 2005 (http://www.epa.gov/cancer guidelines).
85. USEPA. 2007. Framework for determining a mutagenic mode of action for carcinogenicity using EPA's 2005 cancer guidelines and supplemental guidance for assessing susceptibility from early-life exposure to carcinogens: External Peer Review Drafthttp://www.epa.gov/osa/mmoaframework/pdfs/MMOA-ERD-FINAL-83007.pdf.
86. USEPA OPPTS. 1998. OPPTS Harmonized Test Guidelines Series 870 Health Effects Vol I of III Guideline OPPTS 870.1000-OPPTS 870.4300.
87. Venier P, Montaldi A, Majone F, Bianchi V, Levis AG. 1982. Cytotoxic, mutagenic and clastogenic effects of industrial chromium compounds. Carcinogenesis 3:1331-1338.
88. Voitkun V, Zhitkovich A, Costa M. 1998. Cr(III)-mediated crosslinks of glutathione or amino acids to the DNA phosphate backbone are mutagenic in human cells. Nucleic Acids Res 26:2024-2030.
89. Watanabe K, Sakamoto K, Sasali T. 1998. Comparisons on chemically-induced mutagenicity among four bacterial strains, Salmonella typhimurium TA102 and TA2638, and Escherichia coli WP2/pKM101 and WP2 uvrA/pKM101: Collaborative study I. Mutat Res 361:142-155.
90. Waters MD, Stack HF, Brady AL, Haroun I, Vainio H. 1988. Use of computerized data listings and activity profiles of genetic and related effects in the review of 195 compounds. Mutat Res 205:295-312.
91. Wild D. 1978. Cytogenetic effects in the mouse of 17 chemical mutagens and carcinogens evaluated by the micronucleus test. Mutat Res 56:319-327.
92. Ye J, Zhang X, Young HA, Mao Y, Shi X. 1995. Chromium (VI)-induced nuclear factor-jB activation in intact cells via free radical reactions. Carcinogenesis 16:2401-2420.
93. Ye J, Wang S, Leonard SS, Sun Y, Butterworth L, Antonini J, Ding M, Rojanasakul Y, Vallyathan V, Castranova V, Shi X. 1999. Role of reactive oxygen species and p53 in chromium (VI)-induced apoptosis. J Biol Chem 274:34974-34980.
94. Zhang J, Li X. 1986. Chromium contamination in the city of JinZhou. JinZhou Health and Anti-Epidemic Station, JinZhou, China. MRID No. 47325701.
95. Zhitkovich A. 2005. Importance of chromium-DNA adducts in mutagenicity and toxicity of chromium (VI). Chem Res Toxicol 18:3-11.
96. Zhitkovich A, Voltkun V, Kluz T, Costa M. 1998. Utilization of DNA-protein cross-links as a biomarker of chromium exposure. Environ Health Perspect Suppl 106:1-7.
97. Zhitkovich A, Shrager S, Messer J. 2000. Reductive metabolism of Cr (VI) by cysteine leads to the formation of binary and ternary Cr-DNA adducts in the absence of oxidative DNA damage. Chem Res Toxicol 13:1114-1124.
98. Zhitkovich A, Quievryn G, Messer J, Motylevich Z. 2002. Reductive activation with cysteine represents a chromium (III)-dependent pathway in the induction of genotoxicity by carcinogenic (VI). Environ Health Perspect Suppl 110:729-731.